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Abstract 
Background: Breast cancer is the second most common cancer now, after lung cancer, when ranked by cancer 
occurrence in both sexes. The aim of this study was to determine the correlation between various modifiable and non 
modifiable risk factors among women with HER2/neu positive breast cancer attending at Medical College and 
Hospital, Kolkata. Materials & Methods: A cross sectional analytical epidemiological study in Out Patient 
Department & Emergency Department of General Surgery, Medical College& Hospital, Kolkata. Period of study 
was between January 2018 to June 2019. All the adult breast cancer patients attending Department of General 
Surgery, Medical College & Hospital, Kolkata were included in the study and that came out to be 25 HER2 neu 
positive and 35 HER2 neu negative patients. All together 60 patients were included. Results: We have found 60 
patients among them 25 patients were HER2/neu positive and 35 patients were HER2/neu negative i.e. 42% of 
patients in our study found to be HER2/neu positive. Among these patients the patient with minimum age was 38 
years old, and the maximum aged patient was 65 years old.The average age was 57.33 years. The average age of 
HER2/neu positive group was 57.77 years and the HER2/neu negative group was 56.48 years. About 35% of these 
patients had history of OCP intake. Among HER2/neu positive patients 57.1% & HER2/neu negative 42.9% had 
history of OCP intake. Most of the patients in this study are in pre-obese (BMI 25-29.99) class as per BMI. About 
18 HER2/neu positive patients and 26 HER2/neu negative patients are within this group. Five (14.28%) patient in 
HER2/neu negative group and 3 (12%) in HER2/neu positive group has positive family history of breast cancer. In 
our study we have found that menarche of minimum age of 9 years and maximum age at 15 years. Maximum no. of 
patients found their menarche at the age of 12 years. Conclusion: From our study and analysis we could not 
establish any obvious significant difference between epidemiological distributions of breast cancer patients in 
respect to HER2/neu status. Hence this can be concluded from our study that there is no different epidemiological 
pattern of breast cancer in respect to HER2/neu status. 
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Breast cancer is a complex disease encompassing 
multiple tumor entities, each characterized by distinct 
morphology, behavior and clinical implications. It is 
one of the most common malignancies in women. The 
tumour is highly heterogeneous, with a wide range of 
biological, pathological and clinical characteristics. Of 
these characteristics, hormone receptors and HER2/neu 
status has a great influence on the clinical outcome [1].  
It is the second most common cancer now, after lung 
cancer, when ranked by cancer occurrence in both 
sexes. About 55% of the global burden is currently 
experienced in developed countries, but incidence rates 
are rapidly rising in developing countries [2, 3]. For 
decades together, cervical cancer was the most 
common cancer in women in India, and more deaths in 
women in India were attributed to cervical cancer than 
any other cancer [4]. However, over the last 10 years or 
so, breast cancer has been rising steadily, and for the 
first time in 2012, breast cancer was the most common 
cancer in women in India, a way ahead of cervical 
cancer [5]. Estrogens have a crucial role in the 
proliferation and progression of breast cancer. Estrogen 
is the major steroid mitogen for the luminal epithelial 
cell population (the usual target for neoplastic 
transformation) [6]. The role of hormone receptors as 
prognostic and therapeutic tools has widespread 
acceptance in the management of breast cancer. The 
expression of estrogen receptor (ER), in particular, is 
thought to be of great importance, predicting an 
approximately 50% to 75% response rate to hormonal 
therapy. The association between HER2/neu gene (C-
erbB2) amplification and poor prognosis was first 
determined in 1987 by Salmon et al[6], whose results 
showed that amplification of the HER2/neu gene was 
strongly correlated with time to relapse(disease free 
survival) and overall survival. Not only the 
identification of HER2/neu status is important for 
determining the prognosis of breast cancer patients, but 
it is also important for selecting those with metastasis 
for therapy with trastuzumab (herceptin) [7, 8].The aim 
of this study was to determine the correlation between 
various modifiable and non modifiable risk factors 
among women with HER2/neu positive breast cancer 
attending at Medical College and Hospital, Kolkata. 
 
Materials & methods 
 
A cross sectional analytical epidemiological study in 
Out Patient Department & Emergency Department of 
General Surgery, Medical College& Hospital, Kolkata. 
Period of study was between January 2018 to June 
2019. All the adult breast cancer patients attending 
Department of General Surgery, Medical College & 
Hospital, Kolkata were included in the study and that 
came out to be 25 HER2 neu positive and 35 HER2 
neu negative patients. All together 60 patients were 
included. 
Inclusion Criteria 
1. Adult (≥18 years) female breast cancer patients 
attended in OPD & Emergency of Medical college and 
Hospital, Kolkata within the period of data collection. 
2. Patients who had given informed consent 
Exclusion Criteria 
Unconscious, terminally ill patients and those who 
were unable to communicate with the researchers 
excluded. After obtaining necessary permission and 
approval from Institutional Ethics Committee, the 
patients will be approached at out-patient department 
and Emergency ward, General Surgery department, 
Medical college and Hospital, Kolkata.. They were 
explained about the purpose of the study and informed 
consent was obtained. They were interviewed using 
pre-designed questionnaire. Anthropometric 
measurements like height, weight and calculation of 
BMI and clinical examination, general survey and 
systemic examination. Presences of pallor, pulse, blood 
pressure, height, weight were recorded as baseline 
measures in all the cases. Along with these the IHC & 
HPE reports are also used as abasic requirement to 
diagnose the Her 2 neu status of the breast 
carcinoma.For statistical analysis data were entered 
into a Microsoft excel spreadsheet and then analyzed 
by SPSS 24.0. Data had been summarized as mean and 
standard deviation for numerical variables, count and 
percentages for categorical variables. As per necessity 
Chi square test, Independent t test, Mann-Whitney U 




From January 2018 to June 2019, an institution based 
cross sectional, observational and analytical study was 
carried out in the Department of General Surgery and 
Department of Pathology to find out the 
sociodemographic characteristics and disease profile of 
both HER2 neu positive and HER2 neu negative breast 
cancer patients taking a sample size of 60 female 
patients visiting General Surgery OPD of MCH, 
Kolkata. 
HER 2 neu Distribution-In this study we found all 
together 60 patients of breast cancer patients. Among 
them 25 patients were HER 2 neu positive and others 
were HER 2 neu negative i.e. there were 42% of 
patients HER 2 neu positive [Table 1].  
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Table 1: Patient with distribution according to HER2/neu status [n=60] 
Characteristics  Number (Percentage) 
HER2/neu positive 25 (41.67%) 
HER2/neu Negative  35 (58.33%) 
Total no. of CA breast patient  60 (100%) 
In this study we have patients of ages ranging from 38 years to 65 years age. The overall mean age was 
57.33 years and the mode and median both is 58 years [Table 2]. Mean age of HER2/neu positive and negative 
breast cancer patients were found to be 57.77 (4.41) and 56.48 (6.38) years respectively, the differences were not 
found to be statistically significant (p=0.358).  
 
Table 2: Distribution of breast cancer patients according to HER2/neu status and age (n=60) 
Categories Age in years Mean (SD) P value (Using Independent t test) 
HER2/neu Positive  57.77 (4.41)  
0.358 
HER2/neu Negative  56.48 (6.38) 
 
Table 3: Age wise distribution 
Age (Yrs) HER2/neu Positive HER2/neu Negative Total No. of CA breast  
<30 0 0 0 
30 - 39 0 1 1 
40-49 3 1 4 
50-59 14 21 35 
≥60  8 12 20 
 
Role of OCP intake is very much crucial in Breast cancer patients. In our study we have around 21 (35%) of patients 
who had h/o OCP intake. The number of HER2/neu positive patients who has history of OCP intake is 12 and the 
number of HER2/neu negative patients who have taken OCP is 9.Using Chi square test we have found the null 
hypothesis is true. So the differences were not found to be statistically significant (p=0.074) [Table 4]. 
 
Table 4: Association of HER2/neu status and oral contraceptive use among study participants (n=60) 
Categories HER2/neu Positive 
(%) 
HER2/neu Negative (%) P value  
(Chi-square test) 
Used oral contraceptives 12 (57.1) 9 (42.9)  
0.074 
Did not use oral contraceptives 13 (33.3) 26 (66.7) 
 
Body mass index (BMI) is a simple index of weight for height that is commonly used to classify 
underweight overweight and obesity in adults. It is defined as the weight in kilograms divided by the square of the 
height in metres (Kg/m2). In this present study the p value is 0.122, hence the relation between her 2 neu status and 
BMI is statistically insignificant. From the table 5 we can see that maximum (72% for HER2/neu positive 
& 74.3% for HER2/neu negative) patients are in pre-obese group [Table 5]. 
Table 5: Distribution of body mass index with HER2/neu positivity in breast cancer cases 
BMI HER2/neu positive [n=25] HER2/neu negative [n=35] 
Under weight ( <18.5) 2 (8%) 0 
Normal (18.5-24.99) 3 (12%) 7 (20%) 
Pre-obese (25-29.99) 18 (72%) 26 (74.3%) 
Obese class I (30-34.99) 2 (8%) 0 
Obese class II (35-39.99) 0 2 (5.7%) 
Obese class III (≥40) 0 0 
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Table  6: Distribution of study participants according to Her2Nue Status and family history of breast cancer 
(n=60) 
Category  HER2/neu positive [n=25] HER2/neu negative [n=35] P value  
Positive family history 3 (12) 5 (14.28) 0.79 
No family history 22 (88) 30 (85.72) 
 
Proportion of study participants with positive family history among HER2/neu positive and negative patients were 
found to be 62.5% and 57.7% respectively. The differences were not found to be statistically significant (p=0.79) 
[Table 6/Fig. 1]. 
 
Fig  1: Chart comparing between HER2/neu positive and negative patient in respect to family h/o breast 
cancer 
In our study we have found that menarche of minimum age of 9 years and maximum age at 15 years 
.Maximum no. of patients found their menarche at the age of 12 years [Table 7]. 
Table 7: Distribution of age of menarche in patients of breast cancer 
Year of menarchae  HER2/neu positive [n=25] HER2/neu negative [n=35] CA Breast 
9 1 0 1 
10 4 2 6 
11 4 4 8 
12 5 12 17 
13 6 10 16 
14 3 6 9 
15 2 1 3 
In our study we have found maximum patients became mother for first time within the period of 20 to 29 
years of their age. The mode & median value of age of first pregnancy was 20 years. The mean age was 20.62 years. 
The maximum value of age was 28 and the minimum age was 16 [Table 8]. 
Table 8: The pattern of age of first child birth among patients of breast cancer 
Age in yrs HER2/neu positive [n=25] HER2/neu negative [n=35] CA Breast 
<20 11 11 22 
20-29 14 24 38 
≥30 0 0 0 
As there is various hormonal changes occurs during the period of pregnancy. So the no. of completed full 
term pregnancy is important in case of breast cancer. In our study we found lady with maximum h/o full term 
pregnancy upto 7 in numbers. Maximum no. of lady had h/o 3 to 5 child [Table 9]. 
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Table 9: Association of HER2/neu status and total number of child birth among study participants (n=60) 
Categories  Total number of child birth 
Median (IQR)  
P value (Using Mann-Whitney U 
test) 
HER2/neu positive [n=25] 3 (2.5-4) 0.24 
HER2/neu negative [n=35] 4 (3-5) 
 
As the P value of above test is 0.24 so it signifies that the Null hypothesis is valid so there is no significant 
association between HER2/neu status and total no. of child birth [Table 9].As there is obvious hormonal changes 
occurs during any pregnancy, and due to abortion the serial changes suddenly stops, so there become abrupt 
alteration of hormones. Maximum no. of h/o abortion is 3 in HER2/neu positive patients and in Her 2 neu negative 
patients maximum no. of abortion is 2. HER2/neu negative 7 patients & Her 2 neu positive 8 patients had no h/o 
abortion [Table 10]. 
Table 10: Association of HER2/neu status and history of abortion among study participants (n=60) 
Category  HER2/neu positive [n=25] HER2/neu negative [n=35] 
Had h/o Abortion 8 7 
Had no h/o Abortion 17 28 
 
Table 11: Association of HER2/neu Status and total number of abortion among study participants (n=60) 
Categories  Total number of child birth Median (IQR)  P value (Using Mann-
Whitney U test) 
HER2/neu positive [n=25] 1 (0-1.5) 0.51 
HER2/neu negative [n=35] 1 (1-2) 
After using Mann-Whitney U test we get the p value 0.51. Hence the differences between HER2/neu positive and 
negative patients were not statistically significant [Table 11/Fig. 2]. 
 
Fig 2: Graph showing the distribution of h/o abortion in breast cancer patients 
Age of menopause is also important as this is the period till which hormonal changes occur in female body in 
regular interval. In our study we have found that maximum number of patient’s menopause occurred between 46 to 
50 years of age [Table 12]. 
Table 12: Distribution of age of menopause 
Age of menopause HER2/neu positive [n=25] HER2/neu negative [n=35] CA Breast 
40-45 0 6 6 
46-50 15 20 35 
51-55 8 8 16 
>55 0 0 0 
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Discussion 
Breast cancer, is an important health problem 
in India. In the last decade, there is increase of 
knowledge and fast development of breast cancer 
management, which resulted in decrease of mortality 
rates. All women are at risk for developing breast 
cancer. The older a women is, the greater her chances 
of developing breast cancer. Approximately 77% of 
breast cancer cases occur in women over 50 years of 
age. Most important factor in reducing death from 
breast cancer is early detection. Early detection and 
treatment is a key to preventing breast cancer from 
spreading. ER-positive cancers continue to increase 
with age whereas the incidence of ER-negative cancers 
and HER2/neu positive cancers remains relatively 
constant. The number of ER-positive cancers detected 
in older women has risen as a result of mammographic 
screening (which preferentially detects ER-positive 
cancers) and menopausal hormone therapy (which is 
associated with an increase in these cancers). As a 
result, ER-negative and HER2/neu positive cancers 
comprise almost half of cancers in young women but 
fewer than 20% of cancers in older women [9, 10].In 
our study, which is a cross sectional observational 
study, we have taken 60 patients. Among them we 
found 25 patients are HER2/neu positive and 35 
patients are HER2/neu negative. A distinct age-
specific incidence pattern is observed for breast cancer, 
it is characterized by a rapid increase in incidence rate 
before menopause (up to age 50 years) and the rate of 
increase in incidence rates is much lower thereafter. 
This pattern may be due to the diminishing levels of 
circulating estrogens after menopause [11].In our study 
maximum patients (35 within 60) are found at the age 
of 5th decade. However there is no significant 
difference found between patients of HER2/neu 
positive or negative status H/o OCP Intake There are 
multiple types of hormonal contraception available by 
prescription, including OCPs, injectable contraceptives, 
hormonal intrauterine devices (IUDs), implants, 
vaginal rings, and transdermal contraceptive patches. 
OCPs are the most common type of hormonal 
contraception used, though their availability and 
frequency of use vary considerably worldwide. Rates 
of use are generally higher in developed countries, for 
example, in the United States approximately 82% of 
women have ever used OCPs and in 2002 
approximately 11.6 million women of reproductive age 
were currently using OCPs [12]. A multitude of case–
control studies, cohort studies, and pooled analyses 
have assessed the relationship between OCP use and 
risk of breast cancer among pre and post menopausal 
women, including recent studies that have focused on 
timing of use, specific durations of use, and hormonal 
content. Overall, the evidence supports that recent use 
of OCPs is associated with a modest increased risk of 
breast cancer among premenopausal women and that 
this relationship is strongest among very young 
women. In our study, the number of HER2/neu 
positive patients who has history of OCP intake is 12 
and the number of HER2/neu negative patients who 
have taken OCP is 9.Using Chi square test we have 
found the null hypothesis is true. So the differences 
were not found to be statistically significant (p=0.074). 
BMI The physiological manifestation of energy 
balance in humans can be measured by indices of 
nutritional status or body fatness such as BMI, weight 
change, waist–hip ratio (WHR), and height. BMI is 
measured as weight in kilograms (kg) divided by the 
square of height in meters (m2). Although an imperfect 
measure, BMI is highly correlated with percentage of 
body fat [13, 14]. The relationship between BMI and 
breast cancer risk has been extensively studied [14, 
15]. Evidence for an association between BMI and 
breast cancer risk differs by menopausal status in that 
high BMI may be associated with a lower risk of 
premenopausal breast cancer, but is strongly associated 
with a higher risk of postmenopausal breast cancer [16, 
17]. In our study the p value is 0.122, hence the 
relation between HER2/neu status and BMI is 
statistically insignificant. 
Family History  
The accumulation of epidemiologic evidence has 
clarified that the increased risk of breast cancer 
conferred by a positive family history varies with the 
degree of kinship, the number of affected relatives, and 
the onset ages in relatives and/or the women under 
study [18, 19]. In our study proportion of study 
participants with positive family history among 
HER2/neu positive and negative patients were found 
to be 62.5% and 57.7% respectively. The differences 
were not found to be statistically significant (p=0.79). 
Age of Menarche and Menopause  
Perhaps the most compelling evidence regarding the 
influence of endogenous hormones on breast cancer 
risk is found in the levelling off in the age-specific 
incidence curve of breast cancer after menopause when 
ovarian production of steroid hormones ceases. The 
ages at menarche and menopause, milestone events that 
determine the period over which women are exposed to 
endogenous ovarian hormones, have repeatedly been 
shown to be related to the risk of breast cancer [20-23]. 
However we could not found any statistical significant 
difference for HER2/neu status in respect to menarche 
& Menopause Age of first child birth. In a 1970 
landmark study, MacMahon and colleagues concluded 
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that the observed protective effect of parity at least in 
part can be attributed to an earlier age at first birth in 
women with many children [24]. It is now estimated 
that for each additional year of age at first birth, the 
risk of premenopausal breast cancer increases by 5%, 
and increases by 3% for breast cancers diagnosed after 
menopause [25]. Compared to nulliparous women, 
women with a first full-term pregnancy before age 20 
years have about half the risk of breast cancer [26]. 
Women with an older age at first birth (≥35 years) have 
the same risk of breast cancer as nulliparous women. In 
our study we have found maximum patients became 
mother for first time within the period of 20 to 29 years 
of their age. The mode & median value of age of first 
pregnancy is 20 years. The mean age was 20.62 years. 
The maximum value of age was 28 and the minimum 
age was 16. It has long been recognized that parity 
reduces the risk of breast cancer [26]. In our study as 
the P value of above test is 0.24 so it signifies that the 
null hypothesis is valid so there is no significant 
association between HER2/neu status and total no. of 
child birth.  
Total Number of Abortion  
The question whether an incomplete pregnancy affects 
future breast cancer risk has been under much debate. 
Based on findings from animal studies, it has been 
hypothesized that an increase in breast cancer risk may 
follow if the hormonal surge occurring during the first 
trimester is not followed by the protective components 
of breast tissue maturation and terminal differentiation 
of lobular structures during the second and third 
trimester [27]. Findings from early case-control studies 
indicated that induced abortions were associated with 
an increased risk of breast cancer [28]. In our study 
after using Mann-Whitney U test we get the p value 
0.51. Hence the differences between HER2/neu 
positive and negative patients are not statistically 
significant.  
Conclusion 
A cross sectional analytical epidemiological 
study was designed during January 2018 to June 2019. 
The place of study was at Medical College Hospital, 
Kolkata. We have found 60 patients among them 25 
patients were HER2/neu positive and 35 patients were 
HER2/neu negative i.e. 42% of patients in our study 
found to be HER2/neu positive. Among these patients 
the patient with minimum age was 38 years old, and 
the maximum aged patient was 65 years old.The 
average age was 57.33 years. The average age of 
HER2/neu positive group was 57.77 years and the 
HER2/neu negative group was 56.48 years. About 
35% of these patients had history of OCP intake. 
Among HER2/neu positive patients 57.1% & 
HER2/neu negative 42.9% had history of OCP intake. 
Most of the patients in this study are in pre-obese (BMI 
25-29.99) class as per BMI. About 18 HER2/neu 
positive patients and 26 HER2/neu negative patients 
are within this group. Five (14.28%) patient in 
HER2/neu negative group and 3 (12%) in HER2/neu 
positive group has positive family history of breast 
cancer. In our study we have found that menarche of 
minimum age of 9 years and maximum age at 15 years. 
Maximum no. of patients found their menarche at the 
age of 12 years. We have found maximum patients 
became mother for first time within the period of 20 to 
29 years of their age. The mode & median value of age 
of first pregnancy is 20 years. The mean age was 20.62 
years. The maximum value of age was 28 and the 
minimum age was 16. In our study we found lady with 
maximum h/o full term pregnancy upto 7 in no. 
Maximum no. of lady had h/o 3 to 5 child. Maximum 
no. of h/o abortion is 3 in HER2/neu positive patients 
and in HER2/neu negative patients’ maximum no. of 
abortion is 2. HER2/neu negative 7 patients & 
HER2/neu positive 8 patients had no h/o abortion. In 
our study we have found that maximum number of 
patient’s menopause occurred between 46 to 50 years 
of age. From our study and analysis we could not 
establish any obvious significant difference between 
epidemiological distributions of breast cancer patients 
in respect to HER2/neu status. Hence this can be 
concluded from our study that there is no different 
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